Spots Global Cancer Trial Database for Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

Official Title: A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma

Study ID: NCT00498927

Conditions

Brain and Central Nervous System Tumors

Interventions

temozolomide

protein expression analysis

reverse transcriptase-polymerase chain reaction

diagnostic laboratory biomarker analysis

immunoenzyme technique

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent glioblastoma multiforme or other malignant glioma.

Detailed Description: OBJECTIVES: Primary * Determine the progression-free survival rate at 6 months in patients with recurrent glioblastoma multiforme or other malignant glioma treated with temozolomide. Secondary * Determine the overall survival of patients treated with this drug. OUTLINE: Patients receive oral temozolomide once daily in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and every 2 months for 2 years for evaluation of markers of neo-angiogenesis. Samples are analyzed by protein expression, reverse-transcriptase PCR, ELISA, and western blot. (Samples are no longer being collected and tested as of 1/12/09)